Ticker
ADMP

Price
0.22
Stock movement down
-0.01 (-4.30%)
Company name
Adamis Pharma
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Markedsverdi
33.01M
Ent verdi
39.88M
Pris/omsetning
21.43
Pris/bok
11.60
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-64.50%
3 års avkastning
-32.71%
5 års avkastning
-42.82%
10 års avkastning
-32.71%
Sist oppdatert: 2023-02-03

UTBYTTE

ADMP betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning21.43
Pris til bok11.60
EV i forhold til salg25.89

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall149.98M
EPS (TTM)-0.21
FCF per aksje (TTM)-0.21

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)1.54M
Bruttofortjeneste (TTM)-4.25M
Driftsinntekter (TTM)-28.63M
Netto inntekt (TTM)-31.92M
EPS (TTM)-0.21
EPS (1 år fremover)-

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-276.18%
Driftsmargin (TTM)-1858.60%
Fortjenestemargin (TTM)-2072.23%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter2.42M
Netto fordringer1.55M
Samlede omløpsmidler10.09M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler12.14M
Leverandørgjeld5.30M
Kortsiktig/nåværende langsiktig gjeld432.02K
Sum kortsiktig gjeld8.87M
Sum gjeld9.29M
Aksjonærenes egenkapital2.85M
Netto varige driftsmidler2.85M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-31.05M
Kapitalutgifter (TTM)816.10K
Fri kontantstrøm (TTM)-31.84M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-1121.97%
Avkastning på eiendeler-263.03%
Avkastning på investert kapital-993.24%
Kontantavkastning på investert kapital-990.63%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning0.23
Daglig høy0.23
Daglig lav0.22
Daglig volum474K
Tidenes høyeste1835.63
1 år analytikerestimat0.42
Beta1.29
EPS (TTM)-0.21
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon29 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ADMPS&P500
Nåværende prisfall fra toppnotering-99.99%-13.68%
Høyeste prisfall-99.99%-56.47%
Dato for høyeste fall24 Oct 20229 Mar 2009
Gj.snittlig fall fra topp-80.26%-11.49%
Gj.snittlig tid til ny topp252 days13 days
Maks tid til ny topp5717 days1805 days
SELSKAPSOPPLYSNINGER
ADMP (Adamis Pharma) company logo
Markedsverdi
33.01M
Markedsverdi kategori
Small-cap
Beskrivelse
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Ansatte
15
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Dennis J. Carlo
Land
USA
By
San Diego
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q3 2022 Earnings Call Transcript November 14, 2022 Operator: Good afternoon, ladies and gentlemen, and welcome to the Adamis Pharmaceuticals’ Third Qua...
29. desember 2022
Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ETSAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopha...
14. november 2022
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdo...
7. november 2022
Adamis Pharmaceuticals Corp (NASDAQ: ADMP) has initiated a process to explore a range of strategic and financing alternatives. The move follows the recently announced halting of the company's Phase 2/...
4. oktober 2022
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in va...
3. oktober 2022
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infe...
21. september 2022
Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Indep...
21. september 2022
The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO, Sept...
12. september 2022
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announce...
12. august 2022
Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ETSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopha...
10. august 2022
Neste side